SPN 811

Drug Profile

SPN 811

Alternative Names: SPN-811

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Behavioural disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder in USA
  • 23 Feb 2009 Phase-I clinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 23 Feb 2009 SPN 811 is available for licensing (http://www.supernus.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top